015A Stock Chart & Stats
€3.14
€0.00(0.00%)
At close: 4:00 PM EST
€3.14
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.14 - €3.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€52.75M
Enterprise Value€74.13
Total Cash (Recent Filing)€40.65M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 06, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding86,267,030
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.23Price Target Upside66.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet limits leverage and interest obligations, preserving financial flexibility while Rein advances clinical programs. This reduces the risk that fixed debt service competes directly with research spending, although the company remains dependent on equity or other external funding.
LTI-03 Clinical ProgressMeeting the Phase 1b endpoint and advancing into an enrolling Phase 2 trial provide meaningful clinical validation for LTI-03. Tolerability and supportive biomarker movement improve the program’s credibility and could strengthen future partnering or commercialization opportunities.
Reduced Cash BurnThe reduction in cash burn shows some improvement in resource consumption, which can extend the runway relative to prior periods if maintained. Continued discipline would help Rein direct more capital toward clinical execution, though cash generation has not yet become sustainable.
Bears Say
Pre-revenue And Deeply UnprofitableWith no commercial revenue, Rein has no operating inflow to offset substantial development costs, leaving profitability dependent on successful future approvals. The large ongoing loss indicates that the business model remains exposed to prolonged clinical timelines and continued external financing needs.
Persistent Cash ConsumptionPersistent negative operating and free cash flow means the company is consuming capital rather than funding development internally. Unless spending is paired with revenue, partnering proceeds, or a materially lower burn rate, ongoing trials will continue to require financing and constrain strategic flexibility.
Nasdaq Delisting RiskThe Nasdaq notice creates a continuing corporate and financing overhang because failure to regain compliance could lead to suspension or delisting. That outcome could reduce market access and complicate future capital raising while the company is still dependent on external funding.
Rein Therapeutics News
015A FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was €3.14 and its highest was €3.30 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is €52.75M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is Nov 06, 2026 which is in 49 days.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Aug 14, 2026. The company reported -€0.087 earnings per share for the quarter, beating the consensus estimate of -€0.148 by €0.061.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 86,267,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -€0.087 in its last earnings report, beating expectations of -€0.148. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in DE:015A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.23 (66.42% Upside)
€5.23 (66.42% Upside)
Blogger Sentiment
Bullish
DE:015A Sentiment 100%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
015A Stock 12 Month Forecast
Average Price Target
€5.23
▲(66.42% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
XBiotech
―
Elicio Therapeutics
―
Xilio Therapeutics
―